Neuss (ots) - In der kommenden Legislaturperiode - somit ab 2018 - soll das E-Health-Gesetz um einen zweiten ...
The Forgotten Organ - Why to Screen for Exocrine Pancreatic
Malfunction with respect to Diabetes Mellitus!
Tumour Metabolism -
A Novel Concept Closes a Clinical Gap!
Giessen, Germany (ots) - Diabetes mellitus and cancer are among the diseases of greatest clinical focus. At the ScheBo Biotech AG Symposium during MEDICA on the occasion of the World Congress of Pathology and Laboratory Medicine (WASPaLM) 2001 two specific diagnostic tools with unique clinical approaches will be presented.
Since the availability of the ScheBo Pancreatic Elastase 1 stool test, which fulfils all the criteria of a screening test, exocrine pancreatic disturbances can be easily detected without stressing the patient, leading to an appropriate treatment. Moreover, strong evidence has shown that the endocrine pancreatic system (diabetes mellitus) is very closely linked to the exocrine system, and they are influenced by each other.
The decision of the right therapy is one of the major clinical challenges in oncology. Looking for primary effects of carcinogenesis will give additional information about the development of cancer at an early stage ScheBo Tumor M2-PK detects a metabolic switch in cancer cells reflecting the availability of new compounds necessary for fast growth. This meaningful metabolic change is highly specific for tumour cells and not observed in normal proliferating cells. Thus, checking the metabolic state of cancer cells will be the future tool of clinicians to assess the therapy and follow-up the patient. A new concept in diagnosing and following-up patients approaches the oncological clinic.
- Pancreatic Elastase 1 - A Screening Marker for the Second Metabolic Syndrome in Patients with Diabetes Mellitus
- A Unique Approach for Clinical Practice using the Tumor Metabolic Marker Tumor M2-PK
Venue: MEDICA Congress Centre (CCD South), Duesseldorf Germany Date: Thursday 22nd November 2001, 14:00 - 17:00
Please refer to our website for further information: www.schebo.com.
ots Originaltext: ScheBo Biotech AG
Dr. Martin Schoendorf
Product Group Manager International
ScheBo Biotech AG
Netanyastrasse 3 - 5
D-35394 Giessen/ Germany
Tel.: +49 641-4996-0
Fax: +49 641-4996-77